Levothyroxine Sodium Tablets Recalled for Potency Variation and Dosage Failures
Viatris Inc. is recalling 42,331 bottles of Levothyroxine Sodium Tablets 50 mcg distributed nationwide due to potency failures resulting in both superpotent and subpotent tablets.
What this means for you
Real risk of harm even if no illness or injury has been reported yet. Stop using the product and follow the agency's guidance.
Our severity reasoning: This is an FDA Class II recall of a critical thyroid hormone medication with documented potency failures that could affect therapeutic efficacy. The hazard poses a risk of harm through improper thyroid hormone levels, though no illnesses have been reported.
Plain-English summary
Viatris Inc. is recalling Levothyroxine Sodium Tablets USP 50 mcg due to potency failures. The recall affects 42,331 bottles distributed nationwide in the United States and Puerto Rico.
The recalled tablets contain potency variations, with some tablets being superpotent (stronger than labeled) and others being subpotent (weaker than labeled). Levothyroxine is a thyroid hormone replacement medication used to treat hypothyroidism.
The affected lots are: 8174701 (Expiration April 2025), 8182228 (Expiration August 2025), 3193984 (Expiration March 2025), and 3206790 (Expiration August 2025). The affected package NDCs are 0378-1803-77 (90-count bottles) and 0378-1803-10 (1000-count bottles), manufactured for Mylan Pharmaceuticals Inc. in Morgantown, WV.
The recalled product
- Product
- LEVOTHYROXINE SODIUM (LEVOTHYROXINE SODIUM)
- Brand
- LEVOTHYROXINE SODIUM
- Manufacturer
- Viatris Inc
- Category
- Drug — Thyroid Hormone
- Affected units
- 42,331
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (7)
- Lot #: a) 8174701
- Exp. Date April 2025
- 8182228
- Exp. Date Aug 2025 b)3193984
- Exp. Date Mar 2025
- 3206790
- Exp. Date Aug 2025
Distribution
Part of a larger recall action
This product is one of 11 recalled by Viatris Inc under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.
See all 11 products in this recall →Related recalls
Same brand · LEVOTHYROXINE SODIUM
- SevereAccord Recalls Subpotent Levothyroxine Sodium Tablets Nationwide
FDA (Drugs) · 2026-09-02
- HighAccord Healthcare Recalls Subpotent Levothyroxine Sodium Tablets
FDA (Drugs) · 2026-09-02
- SevereAccord Healthcare Recalls Subpotent Levothyroxine Sodium Tablets Nationwide
FDA (Drugs) · 2026-09-02
- ModerateAccord Recalls Subpotent Levothyroxine Sodium Tablets Nationwide
FDA (Drugs) · 2026-09-02
- SevereAccord Recalls Subpotent Levothyroxine Sodium Tablets Nationwide
FDA (Drugs) · 2026-09-02
Same manufacturer · Viatris Inc
See all →- HighXanax XR 3 mg extended-release tablets fail dissolution specifications
FDA (Drugs) · 2026-04-15
- ModeratePrescription Drug Cardura XL Recalled for Out-of-Specification Impurity
FDA (Drugs) · 2025-01-22
- HighPrescription Drug Cardura Recalled for Specification Failures in Manufacturing
FDA (Drugs) · 2025-01-22
- HighLevothyroxine Sodium Tablets recalled nationwide for potency failures
FDA (Drugs) · 2024-12-18
- HighLevothyroxine Sodium Tablets Recalled Due to Potency Failures
FDA (Drugs) · 2024-12-18
Same hazard · potency variation
See all →- HighFDA Recalls Levothyroxine Sodium Tablets for Potency Variation
FDA (Drugs) · 2024-12-18
- LowTeligent Pharma Recalls Clobetasol Propionate Ointment Due to Potency Issues
FDA (Drugs) · 2020-12-09
- SeverePharMEDium Recalls Hydromorphone Syringes Due to Potency Issues
FDA (Drugs) · 2018-06-20
- SeverePfizer Recalls Diphenoxylate and Atropine Tablets Due to Potency Variations
FDA (Drugs) · 2018-01-10
- SeverePfizer Recalls Zoloft Tablets Due to Weight Variations
FDA (Drugs) · 2018-01-10